1 January 2009 in General Physiology and Biophysics
Dietary supplementation with arachidonic acid but not eicosapentaenoic or docosahexaenoic acids alter lipids metabolism in C57BL/6J mice
1 December 2011 in Acta Cardiologica
Purpose Drug-eluting stents (DES) are unique in allowing sustained release after a single short intervention. The challenge with DES still remaining is the optimal combination of a biocompatible drug-eluting matrix including an antiproliferative drug. We studied the role of a novel paclitaxel-eluting stent with a bioabsorbable polymer coating in preventing vascular restenosis in the porcine artery injury model. Material and methods Bare metal stents (BMS); polymer-coated-only stents (POLY); and polymer-based paclitaxel-eluting stents (PACL) were randomly implanted in pig femoral arteries. The dose density of paclitaxel was 1 μ g/mm2 with in vitro studies demonstrating a gradual elution over a course of 6 month. Results After 1-, 3- and 6-month follow-up, respectively, the animals underwent angiographic restudy and were terminated for histomorphometrical and histopathological analyses. At 1 month, the PACL group had the lowest histological percent stenosis when compared to the BMS and POLY groups (20 ± 4% vs 39 ± 6% and 41 ± 6%, respectively, P < 0.05). At 3 months, the PACL group still presents the lowest level of histological percent stenosis among the three groups (27 ± 6% vs 50 ± 10% and 46 ± 5%, respectively, P < 0.01). Six months later, the PACL group showed a similar histological percent stenosis as the BMS and POLY groups (44 ± 9% vs 56 ± 11% and 53 ± 9%, respectively, P= 0.145). Conclusions This study shows favourable vascular compatibility and effi cacy for a novel DES to inhibit in-stent neointima formation and preserve lumen area in the porcine artery model.